European Medicines Agency accepts for filing Marketing Authorization Applica new Itemation for recombinant coagulation factor VIIa (eptacog beta, activated)

Application includes data from phase 3 trials PERSEPT 1, 2, and 3, assessing eptacog beta in treatment of bleeding episodes in children& adults with congenital haemophilia A or B with inhibitors & for prevention of bleeding in those patients undergoing surgery/invasive procedures

Biospace Inc.